UCLA Biodesign Launches Study to Help Advance MedTech and Digital Health Innovation Forward Into a New Decade

| Printer friendly version

What does it require to bring a transformational innovation to patients?  To address this question, the UCLA Biodesign Hub for MedTech and Digital Health has launched an industry-wide study to uncover the cost and time to achieve regulatory and reimbursement approval in the United States and to understand the impact of regulation and reimbursement on the advancement of medical technology and digital health innovation. The last time such a study was conducted was over ten years ago.

The study is led by a research team out of the UCLA Biodesign Hub, in partnership with the life science innovation ecosystem and with support from the U.S. Economic Development Administration. This independent study interviews medtech and digital health regulatory executives to examine trends, establish benchmarks for time and cost to bring transformative technologies to patients, and to inform future decision-making on regulatory and reimbursement.

The questions being explored include:

  • How long does it really take innovations to get to market?
  • Is breakthrough designation breaking down regulatory barriers to access?
  • Is the U.S. keeping pace with Europe, Japan and China?
  • Do digital health and AI/ML have a clear path to market?
  • Is reimbursement the new barrier to innovation?
  • What is next on the regulatory and reimbursement horizon?

Learn more and schedule an interview to participate as a thought leader and build a consensus for innovation policy at www.medtechstudy.com, or contact a member of the research team at info@medtechstudy.com.  Participation will help to establish benchmarks and inform future decision-making for similar companies, and an industry report will be presented at leading conferences in 2021.

 

Sabing Lee
Sabing H. Lee's practice includes strategic patent procurement, patent portfolio management, intellectual property due diligence and general counseling on infringement, licensing, international IP protection and post-grant proceedings. Sabing currently represents clients in a wide range of technologies, with an emphasis on medical devices and procedures and materials science. In the medical device field, Sabing has worked extensively with cardiovascular, orthopedic, wound care and aesthetic technologies. He has been involved in the intellectual property strategy and acquisitions of PercuSurge, Inc. (acquired by Medtronic, Inc.), Flex-Foot, Inc. (acquired by Össur hf.), Endius, Inc. (acquired by Zimmer Holdings, Inc.), ev3 Inc. (acquired by Covidien), IDev Technologies, Inc. (acquired by Abbott), and Tornier NV (merged with Wright Medical Group, Inc.), and CardiAQ Valve Technologies, Inc. (acquired by Edwards Lifesciences Corporation). Sabing currently serves on the Board of Directors for OCTANe, an organization that drives technology industry growth and innovation in Orange County by connecting ideas and people with resources and capital. From 2013-2017, Sabing has been recognized as a Southern California Super Lawyer in Intellectual Property by Super Lawyers magazine. He received Star recognition in the 2012, 2013, 2014, 2015 and 2016 editions of LMG Life Sciences, published by Managing Intellectual Property. Sabing was named to the Daily Journal's list of the Top Intellectual Property Attorneys of 2014, where he was recognized among the Top 25 Portfolio Managers & Patent Prosecutors of Intellectual Property. His accomplishments are detailed in the Awards & Honors section. Sabing joined the firm in 1997 and became a partner in 2003.
View all posts published by Sabing Lee »

Leave a Reply

By using this blog, you agree and understand that no information is being provided in the context of any attorney-client relationship. You further agree and understand that nothing herein is intended to be legal advice. This blog is solely informational in nature, and is not intended as, and should not be used as, a substitute for competent legal advice from a retained and licensed attorney in your state. Knobbe Martens LLP makes no representations or warranties as to the accuracy, completeness, timeliness or availability of the information in this blog. Knobbe Martens LLP will not be liable for any injury or damages relating to your use of, or access to, any such information. Knobbe Martens LLP undertakes no obligation to correct or update information on this blog, which may be incorrect or become incorrect or out of date over time. Knobbe Martens LLP reserves the right to alter or delete content or information on the blog at any time. This blog contains links and references to other websites and publications that you may find of interest. Knobbe Martens LLP does not control, promote, endorse or otherwise have any affiliation with any other websites or publications unless those websites or publications expressly state such an affiliation. Knobbe Martens LLP further has no responsibility for, and makes no representations regarding, the content, accuracy or any other aspect of the information in such websites or publications.